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We investigated the antioxidant properties of two new diarylamines from organic 
synthesis (MJQ1 and MJQ2), whose basic structure is similar to others, with reported 
antioxidant capacity, assessed by chemical tests, and biological activity against 
microorganisms.  
 In this study we induced lipid peroxidation, in isolated rat liver mitochondria with 
ADP/Fe2+, and the diarylamine effects were examined by oxygen consumption and by 
TBARS method. The anti-peroxidative effect was maximal for MJQ1 at 50 nM (higher 
than the one reported for trolox) and for MJQ2 at 60 μM. At these same concentrations 
none of them depressed the transmembrane potential (ΔΨ) developed by mitochondria, 
neither the RCR nor the ADP/O ratio values. For 2-fold these concentrations both 
diarylamines were effective in the prevention of mitochondrial ΔΨ collapse observed on 
respiring mitochondria, with the TPP+ electrode, which means a stabilization action on 
mitochondrial inner membrane.  The results obtained were confirmed in whole cells. 
The compounds did not show toxicity to the L929 cell line, evaluated by the MTT 
reducing test and clearly protected from lipid peroxidation, induced by the oxidant pair 
ascorbate/Fe2+, to the PC12 cell model, at the concentrations where maximal 
antioxidant effect was observed in mitochondria. 
The new diarylamines revealed as very good antioxidants at very low 
concentrations, both in mitochondria and in whole cells. The results suggest a specific 
action site, for MJQ2, at mitochondrial complex I level. We are further exploring other 
intracellular targets for these new compounds that seems very promising against 
pathologies where oxidative stress is involved. 
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